For research use only. Not for therapeutic Use.
GSK1790627 is the N-deacetylated metabolite of Trametinib (HY-10999). Trametinib is an orally active MEK inhibitor, and activates autophagy and induces apoptosis[1].
GSK1790627 (1, 10 and 50 μM, 60 min) is stable in the presence of recombinant hNAT enzymes[1].
| Catalog Number | I041995 |
| CAS Number | 871701-87-0 |
| Synonyms | 1-(3-aminophenyl)-3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione |
| Molecular Formula | C24H21FIN5O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H21FIN5O3/c1-12-20-19(21(29(2)22(12)32)28-18-9-6-13(26)10-17(18)25)23(33)31(15-7-8-15)24(34)30(20)16-5-3-4-14(27)11-16/h3-6,9-11,15,28H,7-8,27H2,1-2H3 |
| InChIKey | JHOKCEWWVHBOFH-UHFFFAOYSA-N |
| SMILES | CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)N)C5CC5 |
| Reference | [1]. Ho MY, et al. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica. 2014 Apr;44(4):352-68. |
